Compare GRFS & DLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRFS | DLB |
|---|---|---|
| Founded | 1940 | 1965 |
| Country | Spain | United States |
| Employees | 25247 | 2051 |
| Industry | Biotechnology: Pharmaceutical Preparations | Multi-Sector Companies |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.8B |
| IPO Year | N/A | 2004 |
| Metric | GRFS | DLB |
|---|---|---|
| Price | $7.83 | $60.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $10.15 | ★ $90.75 |
| AVG Volume (30 Days) | ★ 682.6K | 640.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | 1.79% | ★ 2.29% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.55 |
| Revenue | N/A | N/A |
| Revenue This Year | $5.33 | $6.22 |
| Revenue Next Year | $6.50 | $3.84 |
| P/E Ratio | ★ $18.67 | $114.47 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.19 | $60.14 |
| 52 Week High | $11.14 | $83.25 |
| Indicator | GRFS | DLB |
|---|---|---|
| Relative Strength Index (RSI) | 27.72 | 33.55 |
| Support Level | $7.64 | $60.14 |
| Resistance Level | $9.11 | $67.93 |
| Average True Range (ATR) | 0.29 | 1.58 |
| MACD | -0.12 | -0.42 |
| Stochastic Oscillator | 2.99 | 1.93 |
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Dolby Laboratories Inc. develops technologies that enhance audio and video capture, transmission, and playback, enabling high-quality experiences across movies, TV, music, sports, and more. The company designs and manufactures audio, imaging, accessibility, and related hardware and software mainly for cinema, including digital cinema servers and media encryption and packaging tools. It generates the majority of its revenue by licensing its technology, brand, and patents to device manufacturers and by selling cinema hardware and services. It operates as a single reportable segment, with revenue derived mainly from licensing and, to a lesser extent, from premium cinema technologies, across the United States and international markets.